Drug class
Non-nitrogen-containing bisphosphonate; bone-resorption inhibitor
Mechanism of action
Binds to hydroxyapatite in bone and inhibits crystal growth and dissolution. At sufficient exposure it is taken up by osteoclasts and suppresses osteoclastic bone resorption; unlike nitrogen-containing bisphosphonates it does not inhibit farnesyl pyrophosphate synthase.
General use cases
- Treatment of Paget’s disease of bone
- Prevention and treatment of heterotopic ossification in selected settings
- Treatment of hypercalcaemia associated with malignancy in historical or product-specific settings; check current availability and local label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
